Accessibility and reading comfort

Text size

Light/Dark mode

Lines vertical spacing

Trouble using our website?
Contact us

ERN-EYE publishes two new clinical consensus statements to improve the assessment and management of Rare Eye Diseases

In this page

ERN-EYE is pleased to announce the publication of two new clinical consensus statements, addressing important aspects of ophthalmological care: paediatric keratoconus and the guidance in the assessment of children with low vision.

Developed through the collaboration of numerous ERN-EYE members, patient representatives and experts from across Europe, these publications aim to support healthcare professionals by providing practical, evidence-based recommendations and promoting more harmonised approaches to diagnosis, assessment and patient care.

Paediatric Keratoconus: An ERN-EYE Clinical Consensus Statement on Diagnosis, Treatment and Follow-Up Care

Published in Ophthalmology and Therapy (Springer Nature) on 31 July 2026, this clinical consensus statement provides recommendations for the diagnosis, monitoring and management of paediatric keratoconus. The document covers the disease’s risk factors, clinical features, diagnostic criteria and treatment options. It particularly emphasises the importance of early detection, regular monitoring, patient and family education, and appropriate treatment strategies to prevent disease progression and preserve visual development.

Guidance (challenges and priorities) in the assessment of children with low vision

Published in Survey of Ophthalmology on 6 September 2026, this consensus statement addresses the challenges of assessing visual function in children with low vision, regardless of the underlying cause.

Developed by a multidisciplinary group of experts from eight European countries, together with patient representatives, it provides practical recommendations on the assessment of visual acuity, contrast sensitivity, visual field and colour vision. It highlights the importance of adapting assessment methods to each child’s developmental age, visual impairment and additional needs, to ensure reliable evaluations and support early intervention.

A collaborative effort across the ERN-EYE network

Both publications are the result of many months of dedicated work, involving numerous ERN-EYE members who contributed their clinical expertise, reviewed the scientific literature and participated in the development and validation of the recommendations.

This extensive collaborative process was supported by Dr Amélie Gavard, ERN-EYE’s medical writer, whose expertise and dedication were instrumental in coordinating the process and providing valuable writing support throughout the drafting and development of both consensus statements. 

ERN-EYE warmly thanks all the experts and patient representatives involved for their commitment and valuable contributions. These publications reflect the network’s ongoing commitment to sharing expertise, strengthening European collaboration and improving the quality and consistency of care for people living with Rare Eye Diseases.